2invest AG
SYGNIS AG successfully completes Rights Offering and Private Placement
DGAP-News: SYGNIS AG / Key word(s): Capital Increase PRESS RELEASE
NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN USA, CANADA, JAPAN AND AUSTRALIA SYGNIS AG successfully completes Rights Offering and Private Placement – Rights offering successfully completed and private placement oversubscribed – Acquisition of Expedeon Holdings Ltd. secured – Gross proceeds to cover additional cash payments to Expedeon shareholders and transaction-related expenses mainly Madrid, Spain and Heidelberg, Germany, 15 July 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company has successfully completed its rights offering and the subsequent private placement. Through these transactions, including the contribution in kind, the Company’s share capital will increase by EUR 20,538,089.00 from EUR 16,803,891.00 to EUR 37,341,980.00 through the issue of 20,538,089 shares by way of a rights offering. Existing shareholders subscribed a total number of 3,016,734 new shares. Further 1.801.466 shares were placed at a subscription price of EUR 1.10 per share with qualified investors in a subsequent rump placement, which resulted in gross proceeds of EUR 5.3 million. 15.719.889 remaining shares will be offered to Expedeon shareholders against contribution in kind. Gross proceeds from the cash capital increase will be used for transaction-related expenses, including EUR 1.7 million cash payments to Expedeon shareholders, one-off integration costs and financing working capital. Pilar de la Huerta, CEO and CFO of SYGNIS AG, said: “We would like to thank all our shareholders for supporting this important transaction and are pleased to announce its completion. The acquisition of Expedeon will transform SYGNIS into a truly international player and will not only improve our strategic position but will allow us to achieve important operational and financial milestones.” Heikki Lankriet, CEO of Expedeon, added: “We are excited to become part of the SYGNIS group and look forward to execute our growth strategy and further exploit the huge potential of innovation at SYGNIS and Expedeon.”
About SYGNIS AG: www.sygnis.com SYGNIS, headquartered in Germany and Spain, specializes in the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast-growing fields of molecular biology and next-generation sequencing applications. Key products include the TruePrime(TM) product line and SensiPhi(R), licensed to a leading industry partner, for whole genome DNA amplification and sequencing, as well as the SunScript(TM) Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed on the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03). ### This document is not a securities prospectus and the information contained herein does not constitute an offer to sell or a solicitation of an offer to purchase any securities of SYGNIS AG in the Federal Republic of Germany nor under any other jurisdiction, in particular not where such kind of offer or solicitation is prohibited or lacks the required permission. Potential investors in securities of SYGNIS AG are asked to familiarize themselves with and to observe the respective restrictions. A decision to invest in the securities of SYGNIS AG should only be made on the basis of the securities prospectus detailing the public offering of securities of SYGNIS AG in the Federal Republic of Germany, which, subject to the approval of the German Federal Financial Supervisory Authority (BaFin) is anticipated to be published under www.sygnis.com/investors. The information in this document may not be disseminated outside the Federal Republic of Germany in particular not in the United States, to U.S. Persons (as defined in regulation S of the U.S. Securities Act of 1933) or to publications with a general circulation in the United States with the exception of a such disclosures or announcements outside the Federal Republic of Germany which have to be made under the respective mandatory law. Any person who fails to comply with these restrictions may violate the security laws of certain jurisdictions, in particular of the United States. Securities in SYGNIS AG are not publicly offered outside the Federal Republic of Germany. Some statements included in this press reelease, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
2016-07-15 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English | |
Company: | SYGNIS AG | |
Waldhofer Str. 104 | ||
69123 Heidelberg | ||
Germany | ||
Phone: | +49 (0) 6221 3540 125 | |
Fax: | +49 (0) 6221 3540 127 | |
E-mail: | investors@sygnis.com | |
Internet: | www.sygnis.com | |
ISIN: | DE000A1RFM03 | |
WKN: | A1RFM0 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News Service |